| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |

(From the Department of Anatomy, University of Minnesota Medical School)
Potassium arsenite may actually inhibit and urethane may delay the development of certain lines of transplanted mouse myeloid leukemia, if treatment is begun within a few days after transfer. Increase in survival time, and even complete inhibition, may be obtained by limiting treatment to the first few days after inoculation of leukemic cells. Limited or no protection is provided against transplanted leukemia when these drugs are given after the host is leukemic. It would appear that these findings apply to other agents, such as the folic acid antagonists (18). Other arsenicals and chemicals closely related to urethane may exhibit no "anti-leukemic effect" when given in maximum, tolerable daily doses under the most favorable circumstances, that is, during the "pre-proliferative period" within a few days after transfer, indicating some specificity of drug action. Compounds effective in increasing survival time include those which have been used clinically. It does not follow, however, that materials effective under experimental conditions will provide palliation clinically.
* This investigation has been aided by grants from the National Cancer Institute, The Jane Coffin Childs Memorial Fund for Medical Research, The American Cancer Society, The Donner Foundation, and the Cancer Fund of the Graduate School of the University of Minnesota.
Submitted in partial fulfilment of the requirements for the degree of Master of Science at the University of Minnesota.
Received 10/ 5/49.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |